OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$1.25
0.05 (4.17%)
▲
5d:
+1.63%
30d:
+35.93%
90d:
+10.62%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OGI is 11.6% above its trading range ($1.12). Market expects -4.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OGI is 11.6% above its trading range ($1.12). Market expects -4.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $1.25, which is considered extended relative to its 30-day fair value range of $0.88 to $1.12. From a valuation perspective, the stock is trading at a discount (Forward PE: 52.1) compared to its historical average (59.5). Remarkably, the market is currently pricing in an annual earnings decline of 4.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong uptrend. Immediate support is located at $0.98, while resistance sits at $1.32. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: OGI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+604.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGI is in a strong uptrend. Immediate support is located at $0.98, while resistance sits at $1.32. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: OGI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+604.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.88 -
$1.12
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price significantly overextended (+11.6% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 604.0% below Wall St target ($8.80)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.88 -
$1.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.98
Resistance Level
$1.32
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
52.08
Wall Street Target
$8.80
(+604.0%)
Revenue Growth (YoY)
49.4%
Profit Margin
28.0%
Valuation Discount vs History
-4.3% cheaper
PE vs Historical
52.1 vs 59.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.3%
(market-implied from PE analysis)
1-Year Target
$1.20
(-4%)
2-Year Target
$1.14
(-8%)
3-Year Target
$1.10
(-12%)
3-Yr Target (if PE normalizes)
(PE: 52→60)
$1.25
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 52.1, Growth: -94.6%)
$0.91
(+-27%)
Base:
(SPY PE: 20.1, Growth: -94.6%)
$0.35
(-72%)
Bear:
(PE: 17.1, Growth: -94.6%)
$0.30
(-76%)
📈
Valuation based on Current Earnings
Trailing PE: 2.86 | Current EPS (TTM): $0.42
Bull Case
$0.66
(-47%)
Analyst growth -50.0%, PE expands to 3.1
Base Case
$0.60
(-52%)
Market implied -50.0%, PE stable at 2.9
Bear Case
$0.82
(-35%)
Severe decline -20.0%, PE contracts to 2.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 52.1 to 59.5
Stabilization Target:
$1.43
(+14.2%)
PE Expansion Potential:
+14.2%
Share & Embed Analysis
Last updated: August 23, 2026 8:36 PM ET
Data refreshes hourly during market hours. Next update: 9:36 PM
Data refreshes hourly during market hours. Next update: 9:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
